Ocular Therapeutix, Inc. (OCUL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Ocular Therapeutix, Inc. (OCUL) is down 17.9% since the beginning of the year. At $10 per share, OCUL is trading 39.4% below its 52-week high of $16. Investors who bought $1,000 worth of OCUL shares 5 years ago would now be looking at an investment worth $692.

Ocular Therapeutix, Inc. (OCUL) has returned -17.87% so far this year and 22.63% over the past 12 months. Over the last ten years, OCUL has returned 6.79% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Jul 25, 2014, OCUL's average daily return is +0.12%, while the average monthly return is +2.50%. At this rate, an investment would double in approximately 2.3 years.

Historically, 48% of months were positive and 52% were negative. The best month was Feb 2024 with a return of +107.0%, while the worst month was Jun 2016 at -58.8%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.

On a daily basis, OCUL closed higher 48% of trading days. The best single day was Feb 17, 2016 with a return of +38.5%, while the worst single day was Oct 23, 2015 at -52.3%.

Ocular Therapeutix, Inc. has an annualized alpha of 16.01%, beta of 1.28, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since July 25, 2014.

• This stock participated in 92.09% of S&P 500 Index downside but only 38.79% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

OCUL ranks 53 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Ocular Therapeutix, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ocular Therapeutix, Inc. was 95.19%, occurring on Nov 16, 2023. The portfolio has not yet recovered.

The current Ocular Therapeutix, Inc. drawdown is 76.96%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Ocular Therapeutix, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Ocular Therapeutix, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.